Such down regulation, which was observed in melanoma and colorectal cancer [118,119], is associated with increased metastatic propensity and with the generation of an immune-privileged TME; (ii) perturbations to JAK/STAT1 signaling including epigenetic silencing and inactivating mutations in JAK1 [120,121,122]. This evidence concerns the gene JAK1 and melanoma.